Kana Fujii1, Takayuki Murase1, Shintaro Beppu1,2, Kosuke Saida1, Hisashi Takino1, Ayako Masaki1, Kei Ijichi2, Kimihide Kusafuka3, Yoshiyuki Iida4, Tetsuro Onitsuka4, Yasushi Yatabe5, Nobuhiro Hanai6, Yasuhisa Hasegawa6, Hiroshi Inagaki1. 1. Department of Pathology and Molecular Diagnostics, Graduate School of Medical Sciences, Nagoya City University, Nagoya, Japan. 2. Department of Otolaryngology, Head and Neck Surgery, Graduate School of Medical Sciences, Nagoya City University, Nagoya, Japan. 3. Pathology Division, Shizuoka Cancer Center, Nagaizumi, Shizuoka, Japan. 4. Department of Head and Neck Surgery, Shizuoka Cancer Center, Nagaizumi, Shizuoka, Japan. 5. Department of Pathology and Molecular Diagnostics, Aichi Cancer Center Hospital, Nagoya, Japan. 6. Department of Head and Neck Surgery, Aichi Cancer Center Hospital, Nagoya, Japan.
Abstract
AIMS: Adenoid cystic carcinoma (AdCC) is one of the most common salivary gland malignancies and the long-term prognosis is poor. In this study, we examined alterations of AdCC-associated genes, MYB, MYBL1, MYBL2 and NFIB, and their target molecules, including MYC. The results were correlated to clinicopathological profile of the patients. METHODS AND RESULTS: Using paraffin tumour sections from 33 cases of salivary gland AdCC, we performed a detailed fluorescence in-situ hybridization (FISH) analysis for gene splits and fusions of MYB, MYBL1, MYBL2 and NFIB. We found that 29 of 33 (88%) AdCC cases showed gene splits in either MYB, MYBL1 or NFIB. None of the cases showed an MYBL2 gene alteration. AdCCs were divided genetically into six gene groups, MYB-NFIB (n = 16), MYB-X (n = 4), MYBL1-NFIB (n = 2), MYBL1-X (n = 1), NFIB-X (n = 6) and gene-split-negative (n = 4). AdCC patients showing the MYB or MYBL1 gene splits were associated with microscopically positive surgical margins (P = 0.0148) and overexpression of MYC (P = 0.0164). MYC expression was detected in both ductal and myoepithelial tumour cells, and MYC overexpression was associated with shorter disease-free survival of the patients (P = 0.0268). CONCLUSIONS: The present study suggests that (1) nearly 90% of AdCCs may have gene alterations of either MYB, MYBL1 or NFIB, suggesting the diagnostic utility of the FISH assay, (2) MYB or MYBL1 gene splits may be associated with local aggressiveness of the tumours and overexpression of MYC, which is one of the oncogenic MYB/MYBL1 targets and (3) MYC overexpression may be a risk factor for disease-free survival in AdCC.
AIMS: Adenoid cystic carcinoma (AdCC) is one of the most common salivary gland malignancies and the long-term prognosis is poor. In this study, we examined alterations of AdCC-associated genes, MYB, MYBL1, MYBL2 and NFIB, and their target molecules, including MYC. The results were correlated to clinicopathological profile of the patients. METHODS AND RESULTS: Using paraffintumour sections from 33 cases of salivary gland AdCC, we performed a detailed fluorescence in-situ hybridization (FISH) analysis for gene splits and fusions of MYB, MYBL1, MYBL2 and NFIB. We found that 29 of 33 (88%) AdCC cases showed gene splits in either MYB, MYBL1 or NFIB. None of the cases showed an MYBL2 gene alteration. AdCCs were divided genetically into six gene groups, MYB-NFIB (n = 16), MYB-X (n = 4), MYBL1-NFIB (n = 2), MYBL1-X (n = 1), NFIB-X (n = 6) and gene-split-negative (n = 4). AdCC patients showing the MYB or MYBL1 gene splits were associated with microscopically positive surgical margins (P = 0.0148) and overexpression of MYC (P = 0.0164). MYC expression was detected in both ductal and myoepithelial tumour cells, and MYC overexpression was associated with shorter disease-free survival of the patients (P = 0.0268). CONCLUSIONS: The present study suggests that (1) nearly 90% of AdCCs may have gene alterations of either MYB, MYBL1 or NFIB, suggesting the diagnostic utility of the FISH assay, (2) MYB or MYBL1 gene splits may be associated with local aggressiveness of the tumours and overexpression of MYC, which is one of the oncogenic MYB/MYBL1 targets and (3) MYC overexpression may be a risk factor for disease-free survival in AdCC.
Authors: Jisun Kim; Felipe C Geyer; Luciano G Martelotto; Charlotte Ky Ng; Raymond S Lim; Pier Selenica; Anqi Li; Fresia Pareja; Nicola Fusco; Marcia Edelweiss; Rahul Kumar; Rodrigo Gularte-Merida; Andre N Forbes; Ekta Khurana; Odette Mariani; Sunil Badve; Anne Vincent-Salomon; Larry Norton; Jorge S Reis-Filho; Britta Weigelt Journal: J Pathol Date: 2017-12-28 Impact factor: 7.996
Authors: Jianming Pei; Douglas B Flieder; Arthur Patchefsky; Jacqueline N Talarchek; Harry S Cooper; Joseph R Testa; Shuanzeng Wei Journal: Mod Pathol Date: 2019-04-25 Impact factor: 7.842
Authors: Justin Bubola; Christina M MacMillan; Elizabeth G Demicco; Rose A Chami; Catherine T-S Chung; Iona Leong; Paula Marrano; Zeynep Onkal; David Swanson; Brandon M Veremis; Ilan Weinreb; Lei Zhang; Cristina R Antonescu; Brendan C Dickson Journal: Genes Chromosomes Cancer Date: 2021-07-08 Impact factor: 4.263